Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease

• Published in: Journal of gastroenterology and hepatology Vol. 33; no. 9; pp. 1603 - 1607
• Main Authors: Takedatsu, Hidetoshi, Mitsuyama, Keiichi, Fukunaga, Shuhei, Yoshioka, Shinichiro, Yamauchi, Ryosuke, Mori, Atsushi, Yamasaki, Hiroshi, Kuwaki, Kotaro, Sakisaka, Hideto, Sakisaka, Shotaro, Torimura, Takuji
• Format: Journal Article
• Language: English
• Published: Australia Wiley Subscription Services, Inc 01.09.2018
• Subjects: Antineutrophil cytoplasmic antibodies; Chemiluminescence; Colon; Crohn's disease; Enzyme immunoassay; Granulomatosis; IBD: clinical trials; Immunoglobulins; immunology; Inflammatory bowel disease; Inflammatory bowel diseases; Intestine; microbiology and inflammatory bowel diseases; Minority & ethnic groups; Proteinase; Proteinase 3; screening and diagnosis; Ulcerative colitis; screening and diagnosis; IBD: clinical trials; immunology; microbiology and inflammatory bowel diseases
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/jgh.14140

Background and Aim Proteinase 3 antineutrophil cytoplasmic antibodies (PR3‐ANCAs) are well‐known serological markers for granulomatosis with polyangiitis, but their role as serological markers for inflammatory bowel disease remains uncertain. The present study aimed to evaluate the diagnostic and clinical role of PR3‐ANCAs as markers for inflammatory bowel disease. Methods Using a new methodology with chemiluminescence enzyme immunoassay, serum PR3‐ANCA titers were assessed in 102 patients with ulcerative colitis (UC), 67 patients with Crohn's disease (CD), 44 controls with other intestinal diseases, and 66 healthy controls. Associations with clinical data were investigated. The diagnostic role of PR3‐ANCAs was evaluated by receiver operating characteristic analysis. Results Proteinase 3 antineutrophil cytoplasmic antibody titers were significantly higher in patients with UC than in those with CD patients, patients with intestinal diseases (intestinal controls), and healthy controls (all P < 0.001). Receiver operating characteristic analysis demonstrated an area under the curve of 0.85 (95% confidence interval: 0.83–0.87) and showed that the manufacturer's cutoff value (3.5 U/mL) had a sensitivity of 39.2% and specificity of 96.6% for UC. There was a significant difference between PR3‐ANCA‐positive and PR3‐ANCA‐negative patients with regard to disease duration (P < 0.05) and disease severity (P < 0.01). Conclusions Proteinase 3 antineutrophil cytoplasmic antibodies were significantly more prevalent in patients with UC than in those with CD and controls. Our results suggested the role of PR3‐ANCAs as serological markers for aiding in diagnosing UC and evaluating disease severity. Further prospective studies are needed across multiple populations of patients and ethnic groups.